SIRPA and cancer: Given that CD47-SIRPα signaling enables malignant cells to avoid macrophage-mediated phagocytosis, the inhibition of the CD47-SIRPα signaling axis represents a promising therapeutic strategy for the treatment of cancer, and multiple CD47 targeted drugs have entered the clinical trials.